RenovoRx Inc. has announced the initiation of patient treatment in its clinical trial evaluating the RenovoCath drug delivery device, which is cleared by the U.S. Food and Drug Administration. The first patient was treated at the University of Vermont Cancer Center. Additional clinical sites, including Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center, have joined the PanTheR registry study and are expected to begin patient procedures soon. The results of this study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.